reports
Medpace Holdings Inc: 1 director
A director at Medpace Holdings Inc sold 668 shares at 590.690USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial ...
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu season SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has reached ta...
Cidara Therapeutics Provides Corporate Update and Reports Third Quarte...
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeuticEnrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the Northern Hemisphere by December 2025; Phase 3 initiation triggered $45.0 million milestone payment to JanssenBARDA award to support expanded manufacturing and clinical development of CD388FDA granted Breakthrough Therapy designation to CD388Conference call and webcast today at 5:00 PM...
Fuel Tech Reports 2025 Third Quarter Financial Results
Fuel Tech Reports 2025 Third Quarter Financial Results WARRENVILLE, Ill., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today reported financial results for the third quarter ended September 30, 2025. “We operated profitably in the third quarter, expanded customer relationships for our Air Pollution Control (APC) and FUEL CHEM® business segments, and increased our APC backlog by more than 20% from June ...
Cidara Therapeutics to Participate in November Investor Conferences
Cidara Therapeutics to Participate in November Investor Conferences SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below November investor conferences. Details are as follows: Event: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: November 11, 2025Time: 8:00 AM ETFormat: Fireside Chat Event: Jefferies London Healthcare Conference Date: November 17, 2025Time:...
Fuel Tech Schedules 2025 Third Quarter Financial Results and Conferenc...
Fuel Tech Schedules 2025 Third Quarter Financial Results and Conference Call WARRENVILLE, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today announced that it will issue its financial results for the third quarter ended September 30, 2025 on Tuesday, November 4, 2025 after the close of the stock market. Management will host a conference call on Wednesday, November 5, 2025 at 10:00 am ET / 9:00 am...
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and...
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025 SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its third quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, November 6, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss...
Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 1...
Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025 SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it gave a late-breaking presentation on its non-vaccine influenza preventative candidate, CD388, at the European Scientific Working Group on Influenza (ESWI)’s 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain. “We are encouraged by the trans...
Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation...
Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025 SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it presented late-breaking Phase 2b clinical data on its non-vaccine influenza preventative candidate, CD388, during ID Week 2025, taking place October 19-22, 2025, in Atlanta, GA. “We are pleased to share additional data from our Phase 2b NAVIGATE study at ID Week which furt...
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on ...
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will be presenting late-breaking Phase 2 clinical data on its antiviral influenza candidate, CD388, during ID Week 2025, taking place October 19-22, 2025, in Atlanta, GA. Presentation details are summarized below: Presentation Title: A Randomized, Placebo-controlled Trial to...
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have a late-breaking presentation at the European Scientific Working Group on Influenza (ESWI)’s 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain. Presentation details are summarized below: Late-Breaking Abstract Title: Translational efficacy of CD388, a novel Dru...
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation...
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention Breakthrough Therapy designation comes in addition to previously awarded Fast Track designation SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for CD388 for prevention of influenza A and B in adults and adolescent...
Moody's Ratings affirms FedEx's Baa2 senior unsecured rating; outlook...
Moody's Ratings (Moody's) affirmed the ratings of FedEx Corporation ("FedEx"), including the Baa2 senior unsecured rating and the P-2 short-term rating. We also affirmed the ratings of Federal Express Corporation, including the Baa2 senior unsecured rating and the Aa3 rating of the Pass-Through Cert...
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufact...
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has received an award valued up to $339M from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Departm...
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCH...
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations - Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeu...
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan fo...
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza - Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be sufficient for BLA approval - Phase 3 study population expanded to include adults over 65 years of age in addition to subjects with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cidar...
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE ...
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting - Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in late-breaking presentation - Preclinical data demonstrating potential efficacy of CD388 to prevent H5N1 infection featured in oral presentation SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop...
Fuel Tech to Present at H.C. Wainwright 27th Annual Global Investment ...
Fuel Tech to Present at H.C. Wainwright 27th Annual Global Investment Conference WARRENVILLE, Ill., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today announced that President & CEO Vincent J. Arnone is scheduled to present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York City. Presentation Date & Time: September 9, 2025 at 1:00 pm Eastern ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.